

**CONDITIONAL PETITION FOR EXTENSION OF TIME**

If any extension of time for this response is required, Applicants request that this be considered a petition therefore. Please charge the required fee to Deposit Account No. 14-1263.

**ADDITIONAL FEES**

Please charge any further insufficiency of fees, or credit any excess to Deposit Account No. 14-1263.

**REMARKS**

Each objection or rejection has been addressed below.  
Claims 1-6 are pending; claims 7-13 have been withdrawn.

**Sequence Rules**

Applicants regrettably acknowledge lack of compliance with sequence rules requiring proper SEQ ID NO: after sequences indicated in the body of the specification.

It is respectfully requested that the requirement for appropriate corrections be held in abeyance until allowable subject matter is acknowledged.

**35 USC § 112, 1st paragraph**

It is believed rejections under this section have been overcome by amendment.

Claim 1 and claim 6 have been amended to delete terminology directed to fragments, derivatives, etc. Accordingly, the rejection should be withdrawn.

**Anticipation by Luciani**

This rejection is overcome by amendment to claim 1. Specifically, references to 70% identity and hybridization are deleted.

Rejections Based on Bodzioch et al.

Bodzioch is overcome as a reference based on Applicants priority date of 25 September 1998; the filing date of provisional application 60/101706.

Bodzioch's earliest prior art date is August 1999. Therefore, all rejections based on Bodzioch would be properly withdrawn.

CONCLUSION


Allowance of the claims is respectfully requested.

All § 112 issues and the rejections over Luciani have been addressed by amendment.

The rejections over Bodzioch should be overcome in view of Applicants' priority date.

Respectfully Submitted,

Norris, McLaughlin & Marcus  
220 East 42 nd Street  
New York, NY 10017  
Telephone (212) 808-0700  
Facsimile (212) 808-0844

  
Theodore Gottlieb, PhD  
Reg. No. 42, 597

Certificate of Transmission


I hereby certify that this correspondence is being transmitted by facsimile to the U.S. Patent and Trademark Office (Fax No. (703)872-9306

on 22 March 2004.  
(Date)

THEODORE GOTTLIEB

Typed or printed name of transmittor

Signature



IN THE CLAIMS

1. (Currently amended) A polynucleotide comprising ~~a member selected from the group consisting of:~~
  - (a) ~~a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:2;~~
  - (b) ~~a polynucleotide capable of hybridizing to and which is at least 70% identical to the polynucleotide of (a); and~~
  - (c) ~~a polynucleotide fragment of the polynucleotide of (a) or (b).~~
2. (Previously presented) The polynucleotide of claim 1 wherein the polynucleotide is DNA.
3. (Currently amended) A vector containing one or more of the polynucleotides of claim 1 and 2.
4. (Previously presented) A host cell containing the vector of claim 3.
5. (Previously presented) A process for producing a polypeptide comprising:  
expressing from the host cell of claim 4 the polypeptide encoded by said DNA.
6. (Currently amended) A polypeptide selected from the group consisting of
  - (a) a polypeptide encoded by the polynucleotide of SEQ ID NO: 1, or
  - (b) a polypeptide encoded by a polynucleotide that is at least 70% identical with SEQ ID NO: 1, the encoded polypeptide having at least 70% identity with polypeptide of SEQ ID NO: 2, and having the deduced amino acid sequence of SEQ ID NO:2 and fragments, analogs and derivatives thereof, and  
a polypeptide comprising amino acid 1 to amino acid 2201 of SEQ ID NO:2.
7. - 13. (Canceled).